Close Menu

sequencing-based diagnostics

NEW YORK (GenomeWeb) – Roswell Park Cancer Institute today said that the New York State Department of Health has granted approval for the institute to test cancer patients using its OmniSeq Target molecular diagnostic test.

NEW YORK (GenomeWeb) – Tute Genomics announced that it will provide next-generation sequencing analytics for a molecular diagnostic test being developed by Lineagen for developmental delay, autism spectrum disorders, and other disorders of childhood development.

NEW YORK (GenomeWeb) – Sophia Genetics, a developer of bioinformatics for analyzing genetic test data, today said that it has raised $13.75 million in a Series B financing round.

NEW YORK (GenomeWeb) − Competition for non-invasive prenatal testing in Germany is heating up, with Illumina announcing this week that it has teamed up with a German diagnostic laboratory and other European labs to transfer Verinata's test technology to those countries, and LifeCodexx saying last

NEW YORK (GenomeWeb) – Appistry said today that it has signed a deal to include Personal Genome Diagnostics' CancerSelect panel in the recently released Appistry CloudDx genomics testing service.

NEW YORK (GenomeWeb) – N-of-One today said that it will provide OncoDNA with clinical interpretation services for its next-generation sequencing and other molecular tests for patients throughout Europe.

NEW YORK (GenomeWeb News) – Sequenom said in a regulatory filing today that the US Patent and Trademark Office, Patent Trial and Appeal Board has made rulings favorable to the company in an ongoing dispute with Verinata Health regarding noninvasive prenatal testing technologies.

NEW YORK (GenomeWeb News) – CollabRx announced today that The Jackson Laboratory will incorporate the firm's data analysis solutions into genetic sequencing-based cancer tests that the lab offers to physicians.

This article has been corrected to reflect that Illumina will seek Chinese FDA approval for a MiSeqDx-based NIPT assay, not a HiSeq2500-based assay, as previously reported.

NEW YORK (GenomeWeb News) – Alliance Global today said that it has signed an agreement with Amgen to provide cancer mutation testing in certain countries in the Middle East and Africa.

Pages

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.